Oncoinvent publishes normal tissue dosimetry results from Radspherin trial
Clinical dosimetry results from Phase 1 studies of Radspherin in ovarian and colorectal cancer show absorbed doses to normal organs well below toxicity risk values. These findings align with the observed favorable safety profile and support the treatment's potential.
Oncoinvent has published key findings from its Phase 1 studies of Radspherin, a treatment candidate for ovarian and colorectal cancer. The results appeared in the Journal of Nuclear Medicine.
The published data indicate that absorbed doses to normal organs from Radspherin remained significantly below levels associated with known toxicity risks. These findings are consistent with the favorable safety profile observed to date and support the treatment's potential in future cancer therapies.
The study focused on the dose distribution and safety of the radiopharmaceutical agent Radspherin (225Ra-NN-NOA-APN). Data were collected from patients undergoing treatment as part of the Radio-Gastro-Oncology program. The objective was to quantify radiation exposure to critical organs, including the liver, spleen, and bone marrow.
Oncoinvent is continuing the development of Radspherin as a potential therapeutic option for specific cancer types. The company has previously stated its expectation to commence Phase 2 trials during 2024, pending regulatory approval.